Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients

Advances in Experimental Medicine and Biology

Volumn 756, Issue , 2013, Pages 23-28

  Mroz, R M ^a   Minarowski, L ^a   Chyczewska, E ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Airway; Antimuscarinic agents; COPD treatment; Dyspnea; Indacaterol; Inflammation; Pharmacotherapy; Quality of life; Six minute walking distance; Spirometry

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INDACATEROL; PLACEBO;

ADD ON THERAPY; ADULT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONTROLLED STUDY; DYSPNEA; EXERCISE TOLERANCE; EXPIRATORY RESERVE VOLUME; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY; ST GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION;

EID: 84867504770     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-4549-0_4     Document Type: Conference Paper

References (20)

1. Bailey, S. P., Brown, L., & Bailey, E. K. (2008). Lack of relationship between functional and perceived quality of life outcomes following pulmonary rehabilitation. Cardiopulmonary Physical Therapy Journal, 19 (1), 3-10.
2. Beeh, K. M., Wagner, F., Khindri, S., & Drollmann, A. F. (2011). Effect of indacaterol on dynamic lung hyperin fl ation and breathlessness in hyperin fl ated patients with COPD. COPD, 8 , 340-345.
3. Camargo, L. A., & Pereira, C. A. (2010). Dyspnea in COPD: Beyond the modi fi ed Medical Research Council scale. Jornal Brasileiro de Pneumologia, 36 (5), 571-578.
4. Cazzola, M., Santangelo, G., Piccolo, A., Salzillo, A., Matera, M. G., D'Amato, G., & Rossi, F. (1994). Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology, 7 (2), 103-107.
5. Cazzola, M., Matera, M. G., & Lotvall, J. (2005). Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 14 (7), 775-783.
6. Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., de Montes, O. M., Mendez, R. A., Pinto, P. V., & Cabral, H. J. (2004). The body-mass index, air fl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. The New England Journal of Medicine, 350 (10), 1005-1012.
7. Eisner, M. D., Iribarren, C., Yelin, E. H., Sidney, S., Katz, P. P., Ackerson, L., Lathon, P., Tolstykh, I., Omachi, T., Byl, N., & Blanc, P. D. (2008). Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease. American Journal of Epidemiology, 167 (9), 1090-1101.
8. Ford, E. S., Mannino, D. M., Zhao, G., Li, C., & Croft, J. B. (2011). Changes in mortality among United States adults with chronic obstructive pulmonary disease in two national cohorts recruited during 1971 through 1975 and 1988 through 1994. Chest, 141 , 101-110.
9. Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991). The St George's respiratory questionnaire. Respiratory Medicine, 85 (Suppl B), 25-31.
10. Jones, P. W., Barnes, N., Vogelmeier, C., Lawrence, D., & Kramer, B. (2011). Ef fi cacy of indacaterol in the treatment of patients with COPD. Primary Care Respiratory Journal, 20 (4), 380-388.
11. Leckie, M. J., Bryan, S. A., Hansel, T. T., & Barnes, P. J. (2000). Novel therapy for COPD. Expert Opinion on Investigational Drugs, 9 (1), 3-23.
12. Macklem, P. T. (2010). Therapeutic implications of the pathophysiology of COPD. European Respiratory Journal, 35 (3), 676-680.
13. Maesen, F. P., Smeets, J. J., Costongs, M. A., Wald, F. D., & Cornelissen, P. J. (1993). Ba 679 Br, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD. European Respiratory Journal, 6 (7), 1031-1036.
14. Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: Risk factors, prevalence, and future trends. Lancet, 370 (9589), 765-773.
15. Moy, M. L., Reilly, J. J., Ries, A. L., Mosenifar, Z., Kaplan, R. M., Lew, R., & Garshick, E. (2009). Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. Journal of Rehabilitation Research and Development, 46 (5), 643-654.
16. O'Donnell, D. E., Casaburi, R., Vincken, W., Puente-Maestu, L., Swales, J., Lawrence, D., & Kramer, B. (2011). Effect of indacaterol on exercise endurance and lung hyperin fl ation in COPD. Respiratory Medicine, 105 (7), 1030-1036.
17. Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., & Zielinski, J. (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine, 176 (6), 532-555.
18. Sciurba, F., Criner, G. J., Lee, S. M., Mohsenifar, Z., Shade, D., Slivka, W., & Wise, R. A. (2003). Six-minute walk distance in chronic obstructive pulmonary disease: Reproducibility and effect of walking course layout and length. American Journal of Respiratory and Critical Care Medicine, 167 (11), 1522-1527.
19. Tashkin, D. P., & Fabbri, L. M. (2010). Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: Current and future agents. Respiratory Research, 11 , 149.
20. Westwood, M., Bourbeau, J., Jones, P. W., Cerulli, A., Capkun-Niggli, G., & Worthy, G. (2011). Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: A systematic review. Respiratory Research, 12 , 40.